FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:1528-1530 April 6, 2006 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by The Breast International Group (BIG) 1-98 Collaborative Group PubMed Citation

To the Editor: The report on the Breast International Group (BIG) 1-98 trial (Dec. 29 issue)¹ highlights apparently statistically nonsignificant data from subgroups (of patients who had received previous chemotherapy and those who had node-positive disease) and contrasts them with the results of the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial.² We believe that clinical decisions should not be based on subgroup analyses³ when there are no clear reasons for a differential effect of treatment and no statistical evidence of interaction or heterogeneity. (Such test results were not observed in the ATAC trial² and not reported in the BIG . . . [Full Text of this Article]

This article has been cited by other articles:

• Pietras, R. J. (2006). Biologic Basis of Sequential and Combination Therapies for Hormone-Responsive Breast Cancer. The Oncologist 11: 704-717 [Abstract] [Full Text]